F-STAR THERAPEUTICS

F-STAR THERAPEUTICS

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118, is currently being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.

F-star Therapeutics_logo

Industry:
Biotechnology Company

Address:
Eddeva B920, Cambridge, United Kingdom Zipcode CB22 3AT

Country:
United Kingdom

Phone:
44 1223 497 400

Market Cap:
88.00M
Total Revenue:
11.26M
Total Assets:
63.61M
Total Cash:
18.53M

Website Url:
http://www.f-star.com


Key Executives
Name Title Pay Year Born
Dr. Eliot Richard Forster M.B.A., Ph.D. Pres, CEO & Director N/A 1967(53 years old)
Ms. Darlene M. Deptula-Hicks CFO & Treasurer N/A 1957(63 years old)
Dr. Neil Brewis Chief Scientific Officer N/A N/A
Lindsey Trickett VP of Investor Relations & Communications N/A N/A
Dr. Louis Kayitalire Chief Medical Officer N/A N/A



Financial & Stock
Exchange NasdaqGS. Currency in USD. Market state POSTPOST
According to F-star Therapeutics's financial reports the company's revenue in 2020 were 11.26M an decrease(-60.71%) over the years 2019 revenue that were of 28.32M. In 2020 the company's total earnings were -25.62M while total earnings in 2019 were -23.01M( +8.7%).
Company's stock symbol is FSTX. Lastest price : 9.67. Total volume :479.12k Click reload if you want to check the lastest price on market!!!


Site Inspections: http://www.f-star.com

  • Host name: 40.127.225.109
  • IP address: 40.127.225.109
  • Location: Dublin Ireland
  • Latitude: 53.3338
  • Longitude: -6.2488
  • Timezone: Europe/Dublin
  • Postal: D02

Loading ...
Loading ...


More informations about "F-star Therapeutics" on Search Engine

Investor Relations | F-star Therapeutics, Inc.

Investors.f-star.com F-star is a clinical-stage immuno-oncology company focused on transforming the lives of patients with cancer through the development of F-star’s innovative tetravalent mAb 2 bispecific antibodies.

Overview - F-star

F-star.com We are a clinical-stage biopharmaceutical company with an advanced pipeline of multiple immuno-oncology programs dedicated to creating a paradigm-shift in cancer therapy. We listed on NASDAQ in November 2020 following a business combination with Spring Bank Pharmaceuticals.

Pipeline - F-star

F-star.com F-star has a proprietary clinical pipeline of tetravalent mAb 2 bispecifics that are designed to result in focused, potent and safe immune activation with easy to make molecules. F-star is also pursuing clinical trials of SB 11285, an intravenously administered, next generation STING agonist.

Press Releases | F-star Therapeutics, Inc.

Investors.f-star.com F-star Therapeutics to Host Full-Year 2020 Investor Call and Provide Corporate Update on March 29, 2021. PDF Version. Mar 04, 2021 F-star Therapeutics to Present at Upcoming Investor Conferences. PDF Version. Jan 20, 2021 F-star Granted Composition of Matter Patent for FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1.

F-star Therapeutics, Inc. (FSTX) Stock Price, News, Quote

Finance.yahoo.com About F-star Therapeutics, Inc. F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy.

F-star Therapeutics Shows Differentiation of FS222 in 2021

Markets.businessinsider.com Apr 10, 2021 · About F-star Therapeutics, Inc. F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm shift in cancer therapy.

F-star Therapeutics Completes Combination with Spring Bank

Nasdaq.com Nov 20, 2020 · About F-star Therapeutics, Inc. F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. …

Contact Us - F-star

F-star.com F-star Therapeutics Inc Eddeva B920 Babraham Research Campus Cambridge, CB22 3AT UK TEL +44-1223-497400 [email protected] 245 First Street Riverview II

F-star Therapeutics Completes Combination with Spring Bank

Prnewswire.com Nov 20, 2020 · About F-star Therapeutics, Inc. F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. …

F-star Therapeutics Inc - Company Profile and News

Bloomberg.com F-Star Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on advanced pipeline of multiple immuno-oncology programs dedicated to creating a paradigm ...

F-star Therapeutics Inc FSTX - Quotes, Financials, News

Money.usnews.com F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies.

Leadership | F-star Therapeutics, Inc.

Investors.f-star.com Dr. Forster also serves on the boards of directors of F-star Alpha, F-star Beta, F-star Biotechnology, F-star Delta and F-star Therapeutics LLC, in each case from October 2018, and is the sole managing director for F-star GmbH since May 2019. From January 2015 to February 2018, Dr. Forster served as Chief Executive Officer of Immunocore Limited.

F-star Therapeutics, Inc.: F-star Therapeutics Announces

Bloomberg.com Apr 01, 2021 · About F-star Therapeutics, Inc. F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm …

F-star Therapeutics, Inc. Common Stock (FSTX) Stock Quotes

Nasdaq.com F-star Therapeutics, Inc. Common Stock (FSTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

F-star Therapeutics Shows Differentiation of FS222 in 2021

Globenewswire.com Apr 10, 2021 · About F-star Therapeutics, Inc. F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm …

F-star Therapeutics Inc to Host Earnings Call - Yahoo

Finance.yahoo.com Mar 29, 2021 · NEW YORK, NY / ACCESSWIRE / March 29, 2021 / F-star Therapeutics Inc (NASDAQ:FSTX) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 29, 2021 ...

F-star Therapeutics, Inc. (FSTX) Company Profile & Facts

Finance.yahoo.com F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company ...

Technology Platform - F-star

F-star.com OUR BISPECIFIC ANTIBODY PLATFORM Our proprietary technology allows us to make substitutions in the Fc region of a natural antibody, termed an Fcab, creating two additional distinct antigen binding sites.

SEC Filing | F-star Therapeutics, Inc.

Investors.f-star.com Mar 31, 2021 · We have read the statement made by F-star Therapeutics, Inc. (copy attached) which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K of F-star Therapeutics, Inc., dated March 31, 2021. We agree with the statements concerning our Firm contained therein.

FSTX Stock Price | F-star Therapeutics Inc. Stock Quote (U)

Marketwatch.com Apr 09, 2021 · FSTX | Complete F-star Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

FSTX F-star Therapeutics, Inc. Stock Quote

Finviz.com F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments.

F-star Therapeutics, Inc. | LinkedIn

Linkedin.com F-star Therapeutics, Inc. | 5,318 followers on LinkedIn. We are dedicated to developing next-generation immunotherapies to transform the lives of patients with cancer. | F-star is a leading ...

F-star Therapeutics Shows Differentiation of FS222 in 2021

Software.broadcastnewsroom.com Apr 11, 2021 · About F-star Therapeutics, Inc. F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the Company’s goal is to offer patients greater and more durable benefits than current immuno-oncology ...

Careers - F-star

F-star.com F-star seeks high performing, talented and ambitious individuals to grow our team.You will join a strong, dynamic and culturally diverse team of experienced scientific leaders.

F-star Therapeutics Announces First Patient Dosed in First

Finance.yahoo.com About F-star Therapeutics, Inc. F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy.

FSTX | F-star Therapeutics Inc. Analyst Estimates & Rating

Wsj.com F-star Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. FSTX updated stock price target summary.

F-star Therapeutics Completes Combination with Spring Bank

Investors.f-star.com Nov 20, 2020 · About F-star Therapeutics, Inc. F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy.

F-star Therapeutics, Inc. 8-K Apr. 5, 2021 4:03 PM

Seekingalpha.com F-star Therapeutics, Inc. (FSTX) FORM 8-K | Current report | Current report

F-star Therapeutics to Present at Upcoming Investor

Nasdaq.com Mar 04, 2021 · About F-star Therapeutics, Inc. F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm …

F-star Therapeutics Stock Forecast: up to 18.519 USD

Walletinvestor.com F-star Therapeutics Inc () Stock Market info Recommendations: Buy or sell F-star Therapeutics stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the F-star Therapeutics share forecasts, stock quote and buy / sell signals below.According to present data F-star Therapeutics's FSTX shares and potentially its market environment have been in a bullish cycle in ...

F star Therapeutics Stock Quote. FSTX - Stock Price, News

Ih.advfn.com F-star Therapeutics Inc is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the company's goal is to offer patients greater and more durable benefits than immuno-oncology treatments.

F-star Therapeutics Shows Differentiation of FS222 in 2021

Biospace.com Apr 10, 2021 · Study Confirms F-star’s Bispecific Antibody Tetravalency is the Most Efficient Way to Induce Receptor Clustering and Activation. CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to …

Amended Statement of Ownership (sc 13g/a)

Ih.advfn.com Apr 09, 2021 · F-star Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 30315R 107 (CUSIP Number) March 30, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ¨ Rule 13d-1(b) x Rule 13d-1(c) ¨ Rule ...

F-star Therapeutics: New Biologics Platform For

Seekingalpha.com Jan 22, 2021 · F-star Therapeutics (FSTX) is a clinical-stage biotechnology company using their biologics platform to develop new cancer medicines.

Spring Bank Pharmaceuticals and F-star Therapeutics Agree

Globenewswire.com Jul 29, 2020 · About F-star Therapeutics F-star is a clinical-stage biopharmaceutical company delivering tetravalent bispecific antibodies for a paradigm-shift in cancer therapy.

F-star Therapeutics Announces Clearance of Clinical Trial

Prnewswire.com About F-star Therapeutics Inc F-star is a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer. By ...

F-star Therapeutics Announces First Patient Dosed in FS222

Globenewswire.com Jan 04, 2021 · About F-star Therapeutics, Inc. F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm …

Why F-star Therapeutics's Stock is Up During Today's Session

Msn.com F-star Therapeutics's (NASDAQ:FSTX) stock is trading up 2.54% to a price of $10.48. Thursday the stock has been traded at a volume of 4.98 thousand, about 3.97% of its recent 30-day volume average ...

FSTX | F-star Therapeutics Inc. Company Profile

Wsj.com Company profile for F-star Therapeutics Inc. including key executives, insider trading, ownership, revenue and average growth rates. View detailed FSTX description & address.

F-star Therapeutics: Merck KGaA, Darmstadt, Germany Takes

Finance.yahoo.com Jul 16, 2020 · F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company focused on transforming the lives of patients with cancer through the development of …

FSTX F-star Therapeutics Inc — Stock Price and Discussion

Stocktwits.com Apr 09, 2021 · F-star Therapeutics Inc NASDAQ Updated Apr 9, 2021 10:47 PM. FSTX 10.42 0.29 (2.71%). Post-Market 0.00 (0.00%)

Why Is It Moving? Analyzing The Upward Movement in F-star

Benzinga.com Mar 25, 2021 · F-star Therapeutics’s (NASDAQ:FSTX) stock is trading up 24.69% to a price of $13.79. Thursday the stock has been traded at a volume of 147.87 …

F-star Therapeutics | JMP

Jmp.com F-star Therapeutics, a clinical-stage biopharmaceutical company based in Cambridge, UK, and Cambridge, MA, is working to advance first and best-in-class immunotherapies for patients with late-stage cancer. Central to F-star’s efforts is its proprietary Modular Antibody Technology TM, a platform that introduces two additional antigen-binding ...